15-min delayed · Jul 27, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 2 firms covering ImmunoPrecise Antibodies Ltd, 2 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets are tightly clustered, $5.00 to $5.00, so the covering firms are broadly aligned. The average target of $5.00 sits 247% above the current $1.44. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 1 to 2 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.05 next quarter toward $-0.17 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS2 ratings
Moderate Buy
Strong Buy00%
Buy2100%
Hold00%
Sell00%
Strong Sell00%
Based on 2 analysts giving stock ratings to ImmunoPrecise Antibodies Ltd.
As of Jul, 2 of 2 firms rate HYFT a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
HYFT EPS & revenue forecast
EPS · NEXT QUARTER
$-0.05
Range $-0.06 – $-0.04 · 2 analysts · -2% YoY
Next period, 2 analysts expect ImmunoPrecise Antibodies Ltd. to earn $-0.05 a share (range $-0.06 – $-0.04), versus $-0.05 a year earlier. Full-year consensus is $-0.22, growing to $-0.17 the year after.
REVENUE · NEXT QUARTER
$4.8M
Range $4.5M – $5.1M · 2 analysts · +17% YoY
Revenue is expected to reach $4.8M (range $4.5M – $5.1M), +16.9% year-over-year. Full-year consensus is $19.3M, rising to $24.9M next year.
Top analysts covering ImmunoPrecise Antibodies Ltd.
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on HYFT.
#1
Swayampakula Ramakanth
HC Wainwright & Co. · Rank #230
Buy
$5.00+247.2% to target
Overall win rate
37%
+ Follow
#2
RW
Robert Wasserman
Benchmark · Rank #259
Buy
$3.00+108.3% to target
Overall win rate
39%
+ Follow
#3
DC
Debanjana Chatterjee
Jones Trading
Buy
$5.00+247.2% to target
Coverage
—
+ Follow
#4
DC
Debanjana Chatterjee
JonesTrading
Buy
$5.00+247.2% to target
Coverage
—
+ Follow
HYFT stock forecast FAQ
What is HYFT's average 12-month price target?+
The 2 analysts with a live target average $5.00 for ImmunoPrecise Antibodies Ltd. over the next 12 months, ranging from a $5.00 high to a $5.00 low.
Is HYFT stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 2 analyst ratings, 2 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
How many Wall Street analysts cover HYFT?+
2 analysts have an active rating on ImmunoPrecise Antibodies Ltd., and 2 firms carry a live 12-month price target.
Who is the most accurate analyst covering HYFT?+
Among analysts who currently cover HYFT, Swayampakula Ramakanth of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #230). Their current call is Buy with a $5.00 target.
What is ImmunoPrecise Antibodies Ltd.'s projected EPS for next quarter?+
The consensus estimate is $-0.05 per share (range $-0.06 – $-0.04) across 2 analysts. Full-year EPS is projected at $-0.22, rising to $-0.17 the following year.
How much revenue is ImmunoPrecise Antibodies Ltd. expected to report next quarter?+
Consensus revenue is $4.8M (range $4.5M – $5.1M). Full-year revenue is projected at $19.3M, growing to $24.9M next year.
Have analysts been upgrading or downgrading HYFT lately?+
As of Jul, 2 of 2 firms rate HYFT a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their HYFT calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
